- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00268749
Glycine Treatment of Prodromal Symptoms
March 28, 2012 updated by: Yale University
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.
Study Overview
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 35 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 14-35
- meets SIPS criteria for psychosis prodrome
Exclusion Criteria:
- current antipsychotic medication
- more than 4 weeks of antipsychotic medication lifetime
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
0.8 g/kg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Scale Of Prodromal Symptoms total score
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Scott W Woods, MD, Yale University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2002
Primary Completion (Actual)
November 1, 2004
Study Completion (Actual)
November 1, 2004
Study Registration Dates
First Submitted
December 20, 2005
First Submitted That Met QC Criteria
December 20, 2005
First Posted (Estimate)
December 22, 2005
Study Record Updates
Last Update Posted (Estimate)
March 29, 2012
Last Update Submitted That Met QC Criteria
March 28, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02T-175
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on glycine
-
Case Western Reserve UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingHealthy | Asthma | Cystic Fibrosis | Severe Persistent AsthmaUnited States
-
Nathan Kline Institute for Psychiatric ResearchObsessive Compulsive FoundationCompleted
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)Completed
-
Massachusetts General HospitalNational Institute on Drug Abuse (NIDA)CompletedSchizophreniaUnited States
-
China Medical University HospitalTaipei City HospitalCompletedObsessive Compulsive DisorderTaiwan
-
Eberhard SchulzBiotikiCompletedStress, Psychological | Motor Activity | Attention DeficitGermany
-
University of VirginiaNational Institute of Allergy and Infectious Diseases (NIAID)Withdrawn
-
Medical University of LodzCompleted
-
Mclean HospitalBrain & Behavior Research FoundationCompleted
-
DaacroOOO MNPK BIOTIKICompletedHealthy | Stress, Psychological | Cognitive ImpairmentGermany